Financing
Medis Revenue Growth
Strong and stable financial performance enables Medis to present a low level of risk to its business partners. Over the past five years, Medis has seen average revenue increases of nearly 16 percent per year, ending the 2020 fiscal year with revenues of €136.1 million, up 11.9 percent year-over-year.
Medis meets Dun & Bradstreet's highest financial credit rating criteria every year. Medis's Dun & Bradstreet rating is 4A1.
Platinum Excellence Award
For 2020, we were officially recognized as one of Slovenia’s most reliable companies entitled to use the internationally recognized status of Platinum Excellence, a symbol of truly exceptional credit. This achievement is the result of an excellent team, state-of-the-art technology, and the desire to be better. We thank our partners, clients, and patients for placing their trust in us and recognizing us as a reliable partner in providing the region’s best possible medical solutions.
Trusted Partner in Complex Regions
Medis is a reliable business partner with excellent references, covering a diverse and complex region in all areas, including finance. Working with us means low risk for our partners, as we take care of and monitor the collection of payments and the management of inventory.
We are a financially stable company, able to allocate resources to projects even before the commercial process begins.
We are committed to being accountable for portfolio development and reducing risk for both partner and Medis. Our significant pharmaceutical, medical, legal and cultural expertise in the region gives us a unique advantage in helping you achieve your strategic goals.
Medis is a reliable and credible business partner with a low risk level. The right level of business diversification, development strategy, and modern and accurate financial planning translates to financial strength. It is critical to balance development and long-term risk. Erna Slana Chief Finance Officer